AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Waldencast plc
Video analysis: WALD
All videosNo video analysis for this stock yet. Request one from our team.
News: WALD
Waldencast plc Announces Intention to Voluntarily Delist from Nasdaq and Deregister its Securities under the Exchange Act
Board to recommend that shareholders approve renaming the Company Milk Makeup plc The Company's Board of Directors has approved the voluntary delisting of the Company's Class A Ordinary Shares and Warrants from Nasdaq and the deregistration of those securities under the Exchange Act. Company expects to file a Form 25 with the SEC on or about September 24, 2026; delisting expected to become effective on or about October 4, 2026, with the last day of trading on Nasdaq expected to be October 2, 2026.
Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint
LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it completed the previously announced sale of its Obagi Medical dermatological skincare and aesthetics business (“Obagi Medical”) to Bridgepoint, one of the world's leading mid-market investors, in a transaction valued at up to $460 million (subject to negotiated deductions and customary adjustments based on closing cash, closing indebtedness, net working capital and transaction expenses), marking a significant step in Waldencast's strategy to strengthen its balance sheet and focus on accelerating the global growth of Milk Makeup.
Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel
LONDON, June 15, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Obagi® saypha® ChIQ™ injectable hyaluronic acid (“HA”) gel, the latest addition to the Obagi® injectable portfolio under the Obagi Medical brand. This approval builds on the launch of Obagi® saypha® MagIQ™ and accelerates Obagi Medical's strategy to establish Obagi as a comprehensive leader at the intersection of advanced skincare and medical aesthetics.
Similar companies
-
Marti Technologies, Inc.
MRT
·
New York Stock Exchange Arca
Compare
-
Duos Technologies Group, Inc.
DUOT
·
NASDAQ
Compare
-
Arbe Robotics Ltd.
ARBE
·
NASDAQ
Compare
-
Silvaco Group, Inc. Common Stock
SVCO
·
NASDAQ
Compare
-
Immersion Corporation
IMMR
·
NASDAQ
Compare
-
Perfect Corp.
PERF
·
New York Stock Exchange
Compare